Qamar Khan, MD
Hematology & Oncology · Westwood, KSNPI 1013003425
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 41.7% of the total. That places this record below the midpoint for hematology & oncology clinicians in KS, where the typical reported total is $1,410.
Across 17 payments — averaging $66.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$474
- AstraZeneca$162
- Genentech, Inc.$149
- Astrazeneca UK Limited$135
- Novartis$92
- Stemline Therapeutics Inc.$85
- plus $38 from 2 others
Across 178 payments — averaging $7046.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seagen Inc.$529K
- Novartis$467K
- Sanofi US Services Inc.$161K
- Eli Lilly$44K
- Astrazeneca UK Limited$35K
- Pfizer$18K
- plus $1K from 1 others
What the payments were for
- Food & beverage$1,12399%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 8 | $474 |
| AstraZeneca | 2 | $162 |
| Genentech, Inc. | 1 | $149 |
| Astrazeneca UK Limited | 1 | $135 |
| Novartis | 1 | $92 |
| Stemline Therapeutics Inc. | 2 | $85 |
| Puma Biotechnology, Inc. | 1 | $26 |
| Gilead | 1 | $12 |
How this compares
$1,135 in reported general payments places this provider in the 45th percentile of 97 hematology & oncology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KisqaliRibociclib Succinate | 65 | $1,038,729 |
| VerzenioAbemaciclib | 52 | $765,936 |
| IbrancePalbociclib | 37 | $559,751 |
| OrserduElacestrant Hcl | 12 | $271,428 |
| TykerbLapatinib Ditosylate | 14 | $109,416 |
| EliquisApixaban | 36 | $26,922 |
| Anastrozole | 549 | $9,695 |
| Letrozole | 242 | $6,587 |
| Exemestane | 42 | $5,741 |
| Tamoxifen Citrate | 168 | $3,661 |
| Alendronate Sodium | 102 | $742 |
| Scopolamine | 13 | $540 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 24 | $412 |
| Dexamethasone | 22 | $402 |
| Prochlorperazine Maleate | 42 | $332 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisKisqali | $92 | $1,038,72965 claims |
| Stemline Therapeutics Inc.Orserdu | $85 | $271,42812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 97 hematology & oncology providers in Kansas.
Other hematology & oncology in Westwood
- Priyanka SharmaWestwood$135K
- Gary DoolittleWestwood$102K
- Sunil AbhyankarWestwood$78K
- Leyla ShuneWestwood$56K
- Anthony SungWestwood$49K
- Anup Kumar Kasi Loknath KumarWestwood$31K
- Prakash NeupaneWestwood$26K
- Muhammad Umair MushtaqWestwood$21K
- Jesus Gonzalez LugoWestwood$4K
- Tahani AtiehWestwood$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.